Employment AgreementEmployment Agreement • November 16th, 2023 • Homology Medicines, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (this “Agreement”), dated as of November 16, 2023, is made by and between Homology Medicines, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Charles Michaud, Jr. (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and effective as of November 16, 2023 (the “Effective Date”).
Q32 BIO INC. SUPPORT AGREEMENTSupport Agreement • November 16th, 2023 • Homology Medicines, Inc. • Pharmaceutical preparations • Delaware
THIS SUPPORT AGREEMENT (this “Agreement”), dated as of November 16, 2023 is made by and among Homology Medicines, Inc., a Delaware corporation (“Homology”), Q32 Bio Inc., a Delaware corporation (the “Company”), and the undersigned holders (each a “Stockholder”) of shares of capital stock (the “Shares”) of the Company.
CONTINGENT VALUE RIGHTS AGREEMENT BETWEEN HOMOLOGY MEDICINES, INC. and EQUINITI TRUST COMPANY, LLC, as Rights Agent Dated as of November 16, 2023Contingent Value Rights Agreement • November 16th, 2023 • Homology Medicines, Inc. • Pharmaceutical preparations • Delaware
THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of November 16, 2023, is entered into by and between Homology Medicines, Inc., a Delaware corporation (“Homology”), and Equiniti Trust Company, LLC, a New York limited liability company (“EQ”), as initial Rights Agent (as defined herein).
LOCK-UP AGREEMENTLock-Up Agreement • November 16th, 2023 • Homology Medicines, Inc. • Pharmaceutical preparations
CONSULTING AGREEMENTConsulting Agreement • November 16th, 2023 • Homology Medicines, Inc. • Pharmaceutical preparations • Massachusetts
THIS CONSULTING AGREEMENT (the “Agreement”), effective as of November 16, 2023 (the “Effective Date”), is made by and between Homology Medicines, Inc., a Delaware corporation (the “Company”), and W. Bradford Smith (“Consultant”).
AGREEMENT AND PLAN OF MERGER by and among: HOMOLOGY MEDICINES, INC.; KENOBI MERGER SUB, INC.; and Q32 BIO INC. Dated as of November 16, 2023Merger Agreement • November 16th, 2023 • Homology Medicines, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of November 16, 2023, by and among HOMOLOGY MEDICINES, INC., a Delaware corporation (“Homology”), KENOBI MERGER SUB, INC., a Delaware corporation and a direct, wholly owned subsidiary of Homology (“Merger Sub”), and Q32 BIO INC., a Delaware corporation (“Q32”). Certain capitalized terms used in this Agreement are defined in Section 1.1.
HOMOLOGY MEDICINES, INC. SECOND AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • November 16th, 2023 • Homology Medicines, Inc. • Pharmaceutical preparations
This SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is entered into effective as of November 16, 2023, by and between Homology Medicines, Inc. (the “Company”) and W. Bradford Smith (“Executive,” and, together with the Company, the “Parties”).
